Does This Change Need a New 510(k), or Does a PCCP Cover It?

What 21 CFR 807.81 Actually Regulates for Device Modifications

For medical device regulatory affairs (RA) and quality assurance (QA) professionals, managing design, material, and manufacturing changes to existing commercial products represents a perpetual compliance challenge. When an engineering team proposes a modification to a legally marketed device cleared under Section 510(k) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), RA leaders must immediately resolve one core statutory question: Does 21 CFR 807.81 require the submission of a new premarket notification at least 90 days before commercial distribution, does an established Predetermined Change Control Plan (PCCP) cleared under FD&C Act section 515C except the filing under 21 CFR 807.81(b)(1)(ii), or does the modification fall below the regulatory threshold and require only internal documentation in the quality management system?

Historically, industry discourse treated device modification decisions as an oversimplified binary: submit a new 510(k) or author an internal 'letter to file' (LTF). That binary has always been legally incomplete, and since the enactment of the Food and Drug Omnibus Reform Act of 2022 (FDORA) and FDA's March 2024 conforming regulations, it is dangerously obsolete. Under current 21 CFR 807.81, an evaluated modification to an existing device resolves into one of four distinct regulatory identities:

1. New 510(k) Required under 807.81(a)(3): The modification could significantly affect safety or effectiveness or represents a major change in intended use, and no paragraph (b) exception applies. A formal 510(k) premarket notification must be submitted to FDA, and commercial distribution is barred under 21 CFR 807.100(a) until FDA issues a written substantial equivalence (SE) order.

2. Cleared PCCP Exception under 807.81(b)(1)(ii): The modification is significant enough that it would normally trigger (a)(3), but an established PCCP cleared under FD&C Act section 515C(b)(2) already covers it, and the change is executed in strict consistency with that authorized plan. A new 510(k) is not required if the change is consistent with that cleared plan. Consistency is a manufacturer finding that FDA can later disagree with; keep the consistency record.

3. Documented QMS Change Without a 510(k): The modification does not trigger 807.81(a)(3)(i) or (a)(3)(ii). The change is thoroughly verified, validated, risk-assessed, and documented within the manufacturer's Quality Management System Regulation (QMSR) records under ISO 13485:2016 Clause 7.3.9 and 21 CFR 820.35. No submission is sent to FDA.

4. Statutory Pending Exception under 807.81(b)(1)(i): A formal Premarket Approval Application (PMA) under Section 515 or a reclassification petition under Section 513(f)(2) (De Novo petition) for the device is actively pending before the Agency. A premarket notification under this subpart is not required while that PMA or 513(f)(2) petition is pending. The exception does not itself authorize commercial distribution, and it does not convert the device into an investigational product.

A fifth, narrow regulatory identity exists under 21 CFR 807.81(b)(2), where an FDA Center Director grants a written exception or alternative under 21 CFR 801.128 or 809.11 for devices held in the Strategic National Stockpile (SNS). Because this exception requires an explicit, individual written determination by the Center Director, it cannot be invoked as a general commercial change pathway.

graph TD
  A["Proposed Modification to Marketed Device"] --> B{"Is this a 510(k) device the person currently has in commercial distribution or is reintroducing?"}
  B -->|"No: Class III PMA"| C["Follow 21 CFR 814.39 / 515C(a)"]
  B -->|"No: 510(k) Exempt"| D["Document under QMSR / general controls; this worksheet does not apply"]
  B -->|"No: First-time 807.81(a)(1) or (a)(2)"| E["Submit an initial 510(k); this worksheet does not apply"]
  B -->|"Yes: In distribution or reintroduction"| F{"Does the change trigger 807.81(a)(3)(i) or (a)(3)(ii)?"}
  F -->|"No: Could not significantly affect S&E and not a major intended-use change"| G["Document in QMS without a new 510(k)"]
  F -->|"Yes: Could significantly affect S&E or major intended use"| H{"Does 807.81(b) except the 510(k)?"}
  H -->|"Cleared 515C PCCP and change consistent (b)(1)(ii)"| I["Implement under cleared PCCP without a new 510(k)"]
  H -->|"Pending PMA or 513(f)(2) petition (b)(1)(i)"| J["Premarket notification not required while pending"]
  H -->|"SNS Center Director written grant (b)(2)"| K["Center Director may treat 801.128 / 809.11 grant as satisfying (a)(3)"]
  H -->|"No paragraph (b) exception"| L["Submit a new 510(k) (Traditional, Special, or Abbreviated format)"]
  L --> M["Commercial distribution barred under 807.100(a) until SE order"]

Confirming In-Distribution 510(k) Identity Before Evaluating Changes

A critical legal prerequisite must be established before conducting any technical change assessment: What is the underlying regulatory status of the device being modified? Under 21 CFR 807.81(a), the duty to submit a premarket notification attaches to 'each person who is required to register his establishment pursuant to § 807.20'. Paragraph (a) then subdivides commercial activities into three distinct regulatory events:

• 21 CFR 807.81(a)(1): The device is being introduced into commercial distribution for the first time; that is, the device is not of the same type as, or is not substantially equivalent to, (i) a device in commercial distribution before 28 May 1976, or (ii) a device introduced for commercial distribution after 28 May 1976 that has subsequently been reclassified into class I or II.

• 21 CFR 807.81(a)(2): The device is being introduced into commercial distribution for the first time by a person required to register, whether or not the device meets the criteria in paragraph (a)(1).

• 21 CFR 807.81(a)(3): The device is one that the person currently has in commercial distribution or is reintroducing into commercial distribution, but that is about to be significantly changed or modified in design, components, method of manufacture, or intended use.

Subparagraphs (a)(1) and (a)(2) govern first-time device commercialization. If a company has never marketed this device type, or if the product is being introduced for the first time, the submission is an initial 510(k) governed by standard substantial equivalence rules (detailed in The Complete Guide to FDA 510(k) Submissions). This worksheet does not apply to first-time submissions. It is exclusively an 807.81(a)(3) change identity worksheet for a device currently in commercial distribution or being reintroduced into distribution following clearance.

Furthermore, two broad categories of medical devices are completely excluded from 21 CFR 807.81(a)(3) modification analysis:

• 510(k)-Exempt Devices: Devices classified under Class I or certain Class II regulations that are exempt from premarket notification pursuant to Section 510(l) or 510(m) of the FD&C Act. While an exemption eliminates the requirement to file under 807.81, manufacturers must remain vigilant regarding exemption limitations under 21 CFR 862.9–892.9. As detailed in our guide on 510(k)-Exempt in 2026: How to Check the QMSR, Registration, and UDI Duties You Owe, changes that introduce a new intended use or different fundamental scientific technology typically mean the 510(k) exemption no longer applies and a 510(k) is required. That first filing is not this (a)(3) change worksheet.

• Class III Premarket Approval (PMA) Devices: Devices approved under Section 515 of the FD&C Act are governed exclusively by 21 CFR Part 814. Modifications to PMA devices are evaluated under 21 CFR 814.39 (PMA supplements) and FD&C Act section 515C(a) (PMA PCCPs). Reviewing PMA changes under 807.81 is a fundamental jurisdictional error; consult our guide on PMA Supplement Types Explained: 180-Day, Panel-Track, Real-Time, 30-Day, and Special for Class III change management.

Evaluating the Significant Modification Threshold Under 807.81(a)(3)

Once in-distribution 510(k) device identity is confirmed, the regulatory inquiry focuses on the statutory change triggers named in 21 CFR 807.81(a)(3). Under the regulation, a premarket notification is required if the device is about to undergo a significant change or modification that satisfies either of two distinct prongs:

• Safety or Effectiveness Prong — 807.81(a)(3)(i): 'A change or modification in the device that could significantly affect the safety or effectiveness of the device, e.g., a significant change or modification in design, material, chemical composition, energy source, or manufacturing process.'

• Intended Use Prong — 807.81(a)(3)(ii): 'A major change or modification in the intended use of the device.'

Notice the precise statutory verb in 807.81(a)(3)(i): could significantly affect. The standard does not require clinical proof of harm or an actual increase in adverse events. Compare the changed device to the most recently cleared version. New or significantly modified risks, including plausible new failure modes, are the kinds of facts the 2017 guidance treats as likely to require a new 510(k); they are not a substitute for that documented comparison.

Similarly, 807.81(a)(3)(ii) addresses a major change or modification in the intended use of the device. FDA's 2017 labeling discussion treats changes to indications for use, new patient populations, a new use environment such as home use, or added diagnostic or therapeutic claims as questions that can meet that major-use threshold. Either (a)(3)(i) or (a)(3)(ii) is independently sufficient to trigger 807.81(a)(3).

The 807.81(b)(1)(ii) Exception: Cleared PCCP Under Section 515C

Prior to 2024, if a modification triggered 807.81(a)(3), submitting a new 510(k) was legally unavoidable. That changed fundamentally with Section 3308 of the Food and Drug Omnibus Reform Act of 2022 (FDORA), which added Section 515C to the FD&C Act (codified at 21 U.S.C. 360e-4). Section 515C established explicit statutory authority for Predetermined Change Control Plans (PCCPs) across both approved (PMA) and cleared (510(k)) devices.

On 15 March 2024, FDA published its final rule, Medical Devices; Technical Amendments (89 FR 18792, FR Doc. 2024-05473), officially conforming 21 CFR 807.81(b)(1) to the statute. Effective immediately upon publication, 21 CFR 807.81(b)(1) was revised to state:

'(b)(1) A premarket notification under this subpart is not required for a device for which: ... (ii) There is a predetermined change control plan cleared under section 515C of the act, provided that the change is consistent with the predetermined change control plan.'

To invoke 807.81(b)(1)(ii) and legally implement a significant change without submitting a new 510(k), two cumulative legal conditions must be met:

1. Legal Existence of an FDA-Cleared PCCP: FDA must have reviewed and cleared an established PCCP under FD&C Act section 515C(b)(2) within an authorized marketing submission. A manufacturer cannot invoke (b)(1)(ii) based on internal plans, prospective proposals, or draft protocols submitted to FDA that have not received formal 510(k) clearance.

2. Strict Consistency with the Authorized Plan: The specific change being implemented must be consistent with the cleared PCCP. FDA's August 2024 device-PCCP draft, which is not for implementation, recommends describing planned modifications, a modification protocol, and an impact assessment; those draft headings are authoring suggestions, not extra 807.81(b)(1)(ii) legal elements. 515C(b)(2) conditions (the device remains safe and effective without the change, and would remain substantially equivalent to the predicate) are the tests FDA uses when clearing a plan, not a substitute for checking whether this change is inside an already-cleared plan.

Furthermore, RA teams must recognize the critical statutory restriction established by FD&C Act section 515C(c) (21 U.S.C. 360e-4(c)). Section 515C(c) explicitly dictates that in making subsequent substantial equivalence determinations, FDA shall not compare a device to changed versions implemented in accordance with an established PCCP as a predicate; only the version cleared prior to modifications made under the PCCP may serve as a predicate device. If your regulatory strategy contemplates using your modified device as a future predicate (see our guide on 510(k) Predicate Devices: How to Find, Evaluate, and Select the Right Predicate), post-PCCP modifications cannot be cited as the predicate baseline.

Pending PMA, De Novo Petitions, and Strategic National Stockpile Exceptions

Beyond the PCCP exception in 807.81(b)(1)(ii), the regulation codifies two additional exceptions that RA managers must understand to avoid misclassifying change identities:

1. Pending Premarket Approval or Reclassification Petition — 807.81(b)(1)(i)

Under 21 CFR 807.81(b)(1)(i), a premarket notification is not required for a device for which 'a premarket approval application under section 515 of the act, or a petition to reclassify under section 513(f)(2) of the act, is pending before the Food and Drug Administration'. This is a procedural suspension rule, not an authorization to bypass premarket review. It applies exclusively when an application is actively pending. An approved PMA is not (b)(1)(i); later PMA changes follow 21 CFR 814.39 and 515C(a). A granted De Novo is not (b)(1)(i); later changes follow the resulting classification, including any 510(k) exemption in that regulation, rather than the pending-petition exception.

2. Strategic National Stockpile Labeling Exceptions — 807.81(b)(2)

Under 21 CFR 807.81(b)(2), the appropriate FDA Center Director may determine that the submission and grant of a written request for an exception or alternative under 21 CFR 801.128 (for medical devices) or 21 CFR 809.11 (for in vitro diagnostic products) satisfies 807.81(a)(3). These provisions are strictly limited to devices and IVDs held in the Strategic National Stockpile (SNS) to address public health emergencies or national defense requirements. RA professionals must never attempt to invoke 807.81(b)(2) for routine commercial packaging or labeling modifications.

Documenting Non-Significant Changes: The 2017 Guidance and QMSR Records

When an engineering modification is analyzed against 21 CFR 807.81(a)(3) and the manufacturer objectively determines that the change could not significantly affect safety or effectiveness and does not modify intended use, the change does not trigger the 510(k) duty. The question then becomes: How must this non-significant determination be legally documented?

The primary reference framework for conducting this evaluation remains FDA's final guidance, Deciding When to Submit a 510(k) for a Change to an Existing Device (issued 25 October 2017). The guidance articulates detailed decision trees across four distinct technological domains:

• Labeling Changes: Evaluating changes to indications for use, warnings, contraindications, and instructions for use.

• Technology, Engineering, and Performance Changes: Evaluating modifications in control mechanisms, operating principles, energy delivery, or dimensional tolerances.

• Materials Changes: Evaluating raw material substitutions, contact duration changes, and biocompatibility profiles under ISO 10993-1.

• In Vitro Diagnostic (IVD) Changes: Evaluating assay formulation, specimen types, cut-off values, and clinical performance parameters.

Throughout the guidance's decision trees and worked appendix examples, the flowcharts terminate in one of two recommended regulatory actions: Submit 510(k) or Letter to file. It is essential to understand that 'letter to file' (LTF) is industry shorthand reflecting FDA's guidance terminology. There is no statutory filing type, application code, or regulation entitled 'Letter to File'. It simply means: document the technical and risk assessment in your internal quality system records without submitting a 510(k) to FDA.

QMSR Record Controls: ISO 13485:2016 and 21 CFR 820.35

When the 2017 guidance was issued, FDA cited former 21 CFR 820.30(i) (design changes) and 820.70(b) (production/process changes). On 2 February 2026, FDA's Quality Management System Regulation (QMSR) became effective. Current 21 CFR 820.10 requires a quality management system that complies with ISO 13485:2016 (incorporated by reference) and the other applicable requirements of part 820. Citing former 820.30(i) as if it were still the standalone design-control section is obsolete. The current 2017 when-to-submit PDF carries a QMSR banner that the document was issued before that effective date; see FDA's QSR to QMSR Transition: What Medical Device Companies Need to Know.

Under the current QMSR framework, documentation supporting a 'no 510(k) required' determination must comply with 21 CFR 820.10 (incorporating ISO 13485:2016 Clause 7.3.9, Control of design and development changes), supported by supplemental record controls under 21 CFR 820.35. FDA's 2017 guidance recommends documenting the decision-making process and the basis for concluding that a new 510(k) is not required. A useful QMS change record typically includes:

• Explicit Baseline Comparison: Comparison of the modified device directly against the most recently cleared 510(k) baseline device, not against intermediate un-cleared internal iterations.

• Risk Analysis and Severity Assessment: A comprehensive risk assessment conducted in accordance with ISO 14971, documenting whether the modification introduces any new failure modes, hazardous situations, or changes the severity or probability of existing risks.

• Objective Verification and Validation Evidence: Test reports, engineering analyses, or biocompatibility assessments demonstrating that predetermined acceptance criteria were met.

• Detailed Regulatory Rationale: A step-by-step walk through the applicable 2017 guidance flowchart explaining why neither 807.81(a)(3)(i) nor (a)(3)(ii) was triggered.

Filing Formats After a 510(k) Is Due: Traditional, Special, and Abbreviated

A pervasive procedural error in medical device change control is treating the Special 510(k) Program or the Abbreviated 510(k) Program as an exception from 21 CFR 807.81(a)(3). They are not exceptions. Traditional, Special, and Abbreviated 510(k)s are optional submission formats chosen only AFTER you have already determined that 807.81(a)(3) requires a new premarket notification.

FDA's September 2019 guidance, The Special 510(k) Program, describes an optional pathway for certain well-defined modifications to a manufacturer's own legally marketed device. Under the September 2019 guidance, a modification is eligible for the Special 510(k) format if:

• Manufacturer's Own Device: The modification is made to the manufacturer's own legally marketed device for which substantial equivalence was already established.

• Well-Established Methods: Performance data are unnecessary, or well-established methods are available to evaluate the change and the results can be sufficiently reviewed in a summary or risk-analysis format. The 2019 guidance no longer uses the 1998 test that Special 510(k)s were limited to changes that did not affect intended use or alter fundamental scientific technology.

• Design Control Demonstration of SE: Well-established, standardized design-control verification and validation methods (such as recognized consensus standards) can form, alongside required 21 CFR 807.87 content, the basis for demonstrating substantial equivalence.

If the methods are not well-established, or the results cannot be reviewed in a summary or risk-analysis format (including many changes that rest on clinical, animal, or cadaver data), FDA's 2019 guidance says a Special 510(k) is generally not appropriate and FDA intends to convert the filing to a Traditional 510(k). FDA generally reviews accepted Special 510(k)s within 30 days of receipt; that is a review practice in the 2019 guidance, not an 807.81(b) exception and not a substitute for 807.100(a). For software and cybersecurity updates, see Special 510(k) for Software and Cybersecurity Changes: Decision Tree and Evidence Package.

Regulatory Boundaries: PMA Supplements, Draft Guidances, and AI PCCP Authoring

To maintain rigorous regulatory precision, RA teams must separate 807.81 identity determinations from adjacent regulatory initiatives and draft policies that do not possess binding legal force:

1. August 2024 PCCP Draft Guidance Is Not for Implementation

In August 2024, FDA published a comprehensive draft guidance entitled Predetermined Change Control Plans for Medical Devices (Docket FDA-2024-D-2338). While this draft outlines FDA's forward-looking thinking on expanding PCCP policies across 510(k), De Novo, and PMA devices—including device-led combination products—it bears an explicit Agency banner: Draft — Not for Implementation. Manufacturers cannot cite this draft to assert that non-cleared PCCP concepts are recognized by FDA, nor does it expand 21 CFR 807.81(b)(1)(ii) beyond plans formally cleared under Section 515C.

2. August 2025 AI-Enabled Device PCCP Guidance Is an Authoring Guide

FDA's guidance, Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence-Enabled Device Software Functions (August 2025), provides specific recommendations for authoring Machine Learning PCCPs. As detailed in our guide on FDA PCCP Guide for AI/ML Medical Devices, that guidance instructs sponsors how to construct Description of Modifications, Modification Protocols, and Impact Assessments for software algorithms. It does not serve as an 807.81 identity worksheet for hardware, materials, sterilization, or manufacturing process changes.

Worked Fictional Change Packet: Evaluating Regulatory Identity

Fictional Manufacturer: Apex Orthopedics LLC (Establishment Registration # 9999999-FICTIONAL) Fictional Legally Marketed Device: Apex Lumbar Fixation System (Model ALFS-200, Product Code MNH, Class II pedicle screw spinal system) Original 510(k) Clearance Order: K999999-FICTIONAL (Cleared 14 October 2023) Proposed Engineering Change: Change in raw material bar-stock supplier for Ti-6Al-4V ELI (Grade 5 Titanium alloy) pedicle screw blanks from Supplier Alpha to Supplier Beta. The raw material specification strictly complies with ASTM F136 and ISO 5832-3. There are zero modifications to screw thread pitch, root diameter, head geometry, surface anodization, manufacturing machining parameters, cleaning, packaging, gamma sterilization dose, or indications for use.

Field-by-Field Regulatory Identity Evaluation

1. Device In-Distribution Identity: The device is a Class II orthopedic implant currently in commercial distribution under an active 510(k) clearance (K999999-FICTIONAL). This is an 807.81(a)(3) in-distribution change evaluation, not a first-time introduction under (a)(1) or (a)(2). The product code (MNH) is a non-exempt Class II spinal pedicle-screw system, and the device is not a Class III PMA.

2. Evaluation of 807.81(a)(3)(i) — Safety or Effectiveness: Walk FDA's 2017 Flowchart C (Materials Changes), not Flowchart B (technology, engineering, and performance). In this labeled fictional packet: C1 (is the device an IVD?) No. C2 (change in material type, formulation, chemical composition, or processing, including a supplier change) Yes — the 2017 text says a supplier change should be answered yes at C2 even when the material remains inside the original specification. C3 (direct or indirect tissue or fluid contact) Yes — permanent bone-contact implant. C4 (new or increased biocompatibility concerns) No, as a fictional manufacturer finding: identical Ti-6Al-4V ELI certified to ASTM F136 / ISO 5832-3, same machining, cleaning, anodization, and gamma dose. C5 (could the change affect performance specifications) No, as a fictional manufacturer finding: no change to thread geometry, dimensions, or processing. Flowchart C then points to documentation rather than a new 510(k). That walk is a 2017 guidance recommendation, not current 807.81, and unexpected verification results should cause the 'no 510(k)' decision to be reconsidered. Conclusion: In this fictional packet, the change could not significantly affect safety or effectiveness. 807.81(a)(3)(i) is not triggered.

3. Evaluation of 807.81(a)(3)(ii) — Intended Use: The indications for use, anatomical site, surgical technique, and contraindications remain 100% identical to K999999-FICTIONAL. 807.81(a)(3)(ii) is NOT triggered.

4. Evaluation of 807.81(b)(1)(ii) — Cleared PCCP Exception: Does Apex Orthopedics possess a cleared PCCP under Section 515C covering supplier qualification? No PCCP was submitted or cleared in K999999-FICTIONAL. However, because 807.81(a)(3) was not triggered, an exception under paragraph (b) is unnecessary.

5. Evaluation of 807.81(b)(1)(i) and (b)(2): No PMA or De Novo petition is pending, and no SNS Center Director grant exists. Neither applies.

6. Final Regulatory Determination: Documented in Quality Management System Without a New 510(k). The engineering change, supplier qualification records, ISO 10993 chemical characterization, ASTM F1717 mechanical test reports, and regulatory rationale are approved under Engineering Change Order ECO-2026-088 and filed in the DHF pursuant to ISO 13485:2016 Clause 7.3.9 and 21 CFR 820.35.

Comparative Counter-Factual Scenario

To illustrate how the regulatory identity flips, assume a secondary scenario: Apex Orthopedics modifies the pedicle screw thread geometry from a standard single-lead thread to an aggressive dual-lead thread with increased pitch to accelerate surgical insertion speed.

• Evaluation under 807.81(a)(3)(i): The modified thread pitch changes the bone-screw interface, insertion mechanics, and pullout behavior. Those performance effects are the kind of design change 807.81(a)(3)(i) names as an example of a change that could significantly affect safety or effectiveness. Therefore, in this fictional counterfactual, the change could significantly affect safety or effectiveness. 807.81(a)(3)(i) is TRIGGERED.

• Evaluation under 807.81(b)(1)(ii): Because no cleared 515C PCCP authorizes thread pitch modifications, the (b)(1)(ii) exception is unavailable.

• Submission Identity: A new 510(k) is legally required. Because this is the manufacturer's own legally marketed device and the fictional packet treats ASTM F1717 construct testing as a well-established method whose results can be reviewed in summary format, the September 2019 Special 510(k) pathway may be an optional filing format. It is still a 510(k). Commercial distribution is prohibited under 21 CFR 807.100(a) until FDA issues a written SE clearance order.

A second labeled fictional fork keeps 807.81(b)(1)(ii) from collapsing into that 510(k) row. Suppose the same K999999-FICTIONAL clearance had included a PCCP granted under section 515C(b)(2) whose planned modifications expressly listed a defined family of thread-pitch changes, and this dual-lead change was executed exactly as that cleared plan specified. The identity would then be 807.81(b)(1)(ii): a 510(k) is not required because the change is consistent with a PCCP already cleared under section 515C. If the dual-lead geometry falls outside that cleared plan, (b)(1)(ii) is unavailable and 807.81(a)(3) is back in play. Do not treat a design-history note, ECO-2026-088, or a 2017 'letter to file' checkbox as that cleared PCCP. This fork is stamped fictional; it does not use a real PCCP identifier.

RA/QA Implementation Checklist and Critical Traps

Before an RA/QA Director signs off on any device modification protocol or regulatory assessment memorandum, cross-reference the proposed action against these five high-risk failure modes:

1. Trap 1: Confusing an Internal ECO with an FDA-Cleared PCCP. Never treat an internal change control protocol or risk evaluation as an authorized PCCP under 807.81(b)(1)(ii). Unless FDA has cleared a PCCP under FD&C Act section 515C(b)(2) and this change is consistent with that plan, 807.81(b)(1)(ii) does not apply.

2. Trap 2: Treating Special 510(k) as an Exemption from Premarket Review. A Special 510(k) is not an exception from 807.81(a)(3). It is a full premarket submission requiring FDA substantial equivalence review. Distributing product before receiving an SE order violates 21 CFR 807.100(a).

3. Trap 3: Creeping Evolution of Baseline Predicates. When assessing cumulative changes, always compare the modified device against the original version cleared by FDA in your most recent 510(k). Comparing changes only against intermediate un-cleared internal iterations results in incremental drift that violates 807.81(a)(3).

4. Trap 4: Disregarding the Predicate Exclusion Under Section 515C(c). If your product incorporates modifications executed under a cleared PCCP, do not list the modified version as a predicate in future 510(k) filings. Section 515C(c) restricts predicate claims exclusively to the version cleared prior to PCCP modifications.

5. Trap 5: Ignoring Unexpected Verification Results. If bench testing, biocompatibility assays, or software verification yield unexpected results, the 2017 guidance says any prior decision that a new 510(k) is not required should be reconsidered. Unexpected results undercut assumptions that the change could not significantly affect safety or effectiveness.

By enforcing strict adherence to 21 CFR 807.81 identity categories, maintaining rigorous QMSR change records under ISO 13485:2016 and 21 CFR 820.35, and properly delineating between cleared Section 515C PCCPs and routine QMS documentation, medical device manufacturers can confidently protect patient safety while navigating complex post-market modifications.

This page is an 807.81 identity worksheet for one change to a legally marketed 510(k) device. It is not Medical Device Change Control: FDA and EU MDR Requirements, not Design Controls for Medical Devices: FDA Requirements, Process, and Implementation Guide, not PMA vs 510(k): Differences, Requirements, and How to Choose the Right FDA Pathway, not AI/ML Medical Devices: FDA Framework, SaMD Classification, Approval Paths, not Adaptive AI Medical Devices: Why an FDA PCCP Won't Update Your Model in the EU or Japan, not PCCP Drift Monitoring for AI Imaging Devices: Thresholds and Retraining Triggers, not Is This Reagent an ASR or a Finished IVD?, and not Does This US IVD Study Need an IDE, an IND, or Neither?. Link those hubs; do not recast them here.